+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Presbyopia - Pipeline Insight, 2021

  • ID: 4989258
  • Clinical Trials
  • October 2021
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • AbbVie
  • Aclaris Therapeutics
  • Cellix Bio
  • Eyenovia
  • Ocularis Pharma
  • Ocuphire Pharma
This “Presbyopia - Pipeline Insight, 2021” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered


  • Global coverage

Presbyopia Understanding


Presbyopia: Overview


Presbyopia is the gradual loss of eyes' ability to focus on nearby objects. It's a natural part of aging. Common symptoms of presbyopia are eyestrain or headaches after reading or doing close work, difficulty reading small print, fatigue from doing close work, overall problems seeing and focusing on objects that are close, or squinting. Presbyopia is diagnosed by a basic eye exam, which includes a refraction assessment and an eye health exam. The goal of treatment is to compensate for the inability of the eyes to focus on nearby objects. Treatment options include wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia.

"Presbyopia - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Presbyopia pipeline landscape is provided which includes the disease overview and Presbyopia treatment guidelines. The assessment part of the report embraces, in depth Presbyopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve Presbyopia.

Presbyopia Emerging Drugs Chapters


This segment of the Presbyopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Presbyopia Emerging Drugs


AGN-190584: AbbVie


AGN-190584 is an investigational, novel optimized formulation of pilocarpine specifically designed for the treatment of presbyopia as a topical, once-daily drop delivered by a proprietary vehicle. The primary mechanism of action is through pupil constriction to enhance depth of focus and improve near and intermediate vision while maintaining pupillary response to different lighting conditions - an effect known as dynamic pupil modulation. The drug is in Preregistration for the treatment of Presbyopia.

BRIMOCHOL: Visus Therapeutics


BRIMOCHOL is a proprietary pupil-modulating eye drop that combines two well-studied, FDA-approved pharmaceuticals: carbachol (a cholinergic agent) and brimonidine tartrate (an alpha-2 agonist). Together, they produce a “pinhole effect,” which reduces the size of the pupil so that only centrally focused light rays are able to enter the eye, thereby sharpening distant and near images while minimizing side effects. The drug is in Phase II clinical studies for the treatment of Presbyopia.

Presbyopia: Therapeutic Assessment


This segment of the report provides insights about the different Presbyopia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Presbyopia


There are approx. 10+ key companies which are developing the therapies for Presbyopia. The companies which have their Presbyopia drug candidates in the most advanced stage, i.e. Preregistration include, AbbVie.

Phases


This report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as


  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as


  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Presbyopia: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Presbyopia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Presbyopia drugs.

Presbyopia Report Insights


  • Presbyopia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Presbyopia Report Assessment


  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Presbyopia drugs?
  • How many Presbyopia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Presbyopia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Presbyopia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Presbyopia and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players


  • AbbVie
  • Orasis Pharmaceuticals
  • Eyenovia
  • Aclaris Therapeutics
  • Ocuphire Pharma
  • Visus Therapeutics
  • Ocularis Pharma
  • Cellix Bio

Key Products


  • AGN-190584
  • AGN-241622
  • CSF-1
  • ARVN-003
  • Oxymetazoline
  • Phentolamine/pilocarpine
  • BRIMOCHOL
  • Phentolamine
  • CLX-OPH-561
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • Aclaris Therapeutics
  • Cellix Bio
  • Eyenovia
  • Ocularis Pharma
  • Ocuphire Pharma

IntroductionExecutive Summary
Presbyopia: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Presbyopia - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis

CSF-1: Orasis Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

BRIMOCHOL: Visus Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I/II)
  • Comparative Analysis

AGN-241622: AbbVie
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical/Discovery Stage Products
  • Comparative Analysis

CLX-OPH-561: Cellix Bio
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Presbyopia Key CompaniesPresbyopia Key ProductsPresbyopia- Unmet NeedsPresbyopia- Market Drivers and BarriersPresbyopia- Future Perspectives and ConclusionPresbyopia Analyst ViewsAppendix
List of Tables
Table 1 Total Products for Presbyopia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Presbyopia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie
  • Orasis Pharmaceuticals
  • Eyenovia
  • Aclaris Therapeutics
  • Ocuphire Pharma
  • Visus Therapeutics
  • Ocularis Pharma
  • Cellix Bio
Note: Product cover images may vary from those shown